Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2004. The report primarily announces a share repurchase transaction, the publication of the 2003 Annual Report, and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It focuses on capital structure changes and corporate governance disclosures.
- Share Repurchase Price: 1,069.98 pence per share.
- Shares Purchased: 930,000 Ordinary Shares.
- Treasury Shares Held: 6,520,000 (post-transaction).
- Shares in Issue: 5,934,526,059 (excluding treasury shares).
- ADR Fund Movement: Decrease from 18,865,547 to 18,846,686 shares at an average price of $39.38.
Material Changes
The primary material change is the reduction of outstanding shares through a buyback authorized by shareholders at the May 19, 2003 Annual General Meeting. Additionally, the filing notes a decrease in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan due to fund movements.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. The document serves as a notification of the availability of the 2003 Annual Report and Corporate Responsibility Report.
Investor Verification Checklist
- Verify the total cost of the 930,000 share repurchase against the stated price of 1,069.98 pence.
- Confirm the updated share count of 5,934,526,059 in issue and 6,520,000 in treasury.
- Review the full 2003 Annual Report and Corporate Responsibility Report available at www.gsk.com for detailed financial performance.
- Check the impact of the US Retirement Savings Plan ADR reduction on director interests for Dr. J-P Garnier and Dr. T Yamada.